throbber
Acta Ophthalmologica Scandinavica 2002
`
`Cyclodextrins in eye drop
`formulations: enhanced topical
`delivery of corticosteroids to
`the eye
`
`Thorsteinn Loftsson1 and Einar Stefa´nsson2
`
`Faculties of Pharmacy1 and Medicine2, University of Iceland
`2Decode Genetics Inc., Reykjavik, Iceland
`
`ABSTRACT.
`Cyclodextrins are cylindrical oligosaccharides with a lipophilic central cavity
`and hydrophilic outer surface. They can form water-soluble complexes with lipo-
`philic drugs, which ‘hide’ in the cavity. Cyclodextrins can be used to form aque-
`ous eye drop solutions with lipophilic drugs, such as steroids and some carbonic
`anhydrase inhibitors. The cyclodextrins increase the water solubility of the drug,
`enhance drug absorption into the eye, improve aqueous stability and reduce
`local irritation.
`Cyclodextrins are useful excipients in eye drop formulations of various drugs,
`including steroids of any kind, carbonic anhydrase inhibitors, pilocarpine, cyclo-
`sporins, etc. Their use in ophthalmology has already begun and is likely to
`expand the selection of drugs available as eye drops.
`In this paper we review the properties of cyclodextrins and their application in
`eye drop formulations, of which their use in the formulation of dexamethasone
`eye drops is an example. Cyclodextrins have been used to formulate eye drops
`containing corticosteroids, such as dexamethasone, with levels of concentration
`and ocular absorption which, according to human and animal studies, are many
`times those seen with presently available formulations. Cyclodextrin-based
`dexamethasone eye drops are well tolerated in the eye and seem to provide a
`higher degree of bioavailability and clinical efficiency than the steroid eye drop
`formulations presently available. Such formulations offer the possibility of once
`per day application of corticosteroid eye drops after eye surgery, and more
`intensive topical steroid treatment in severe inflammation.
`While cyclodextrins have been known for more than a century, their use in
`ophthalmology is just starting. Cyclodextrins are useful excipients in eye drop
`formulations for a variety of lipophilic drugs. They will facilitate eye drop for-
`mulations for drugs that otherwise might not be available for topical use, while
`improving absorption and stability and decreasing local irritation.
`
`Keywords: drug delivery – eye drops – cyclodextrin – steroids – solubility.
`
`Acta Ophthalmol. Scand. 2002: 80: 144–150
`Copyrightc ActaOphthalmolScand2002.ISSN1395-3907
`
`Anew group of pharmaceutical ex-
`
`cipients called cyclodextrins has
`recently been introduced into ophthal-
`mology (Table 1). This group of excipi-
`
`ents is able to solubilize many lipophilic
`water-insoluble drugs which previously
`were impossible to formulate in aqueous
`eye drop solutions. Aqueous cyclodextrin
`
`containing eye drop solutions have al-
`ready been registered in Europe. A chlor-
`amphenicol eye drop solution (Cloroc-
`ilA) was recently registered in Portugal;
`2001 saw the registration of a diclofenac
`eye drop solution (Voltaren Ophthal-
`micA) in France. Previous reviews on this
`subject
`include those by van Dorne
`(1993); Rajewski & Stella (1996); Lofts-
`son & Stefa´nsson (1997); and Loftsson &
`Järvinen (1999). The object of this short
`review is to describe how cyclodextrins
`enhance aqueous solubility and bioavail-
`ability of lipophilic water-insoluble drugs
`in aqueous eye drop formulations. The
`formulation and in vivo testing of dexa-
`methasone eye drops as performed within
`our own research group are used as
`examples.
`
`Corticosteroids in ophthalmology
`The most common use of corticosteroids
`in eye drops is for inflammation following
`eye surgery, such as cataract surgery and
`corneal operations. In mild cases it is
`usually adequate to apply the eye drops
`one to four times per day and in some
`cases topically applied nonsteroidal anti-
`inflammatory drugs may be sufficient.
`However, in cases of severe inflammation,
`such as after complicated eye surgery,
`corneal
`transplant rejection or severe
`uveitis, applications as frequently as once
`every hour may not be adequate. In these
`severe cases the eye drops have to be
`supplemented with systemic
`steroids,
`such as prednisolone, or with subcon-
`junctival or subtenon injection of ster-
`oids. Rather than using commercially
`available eye drops,
`it would then be
`
`144
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1041, Page 1
`
`

`

`Acta Ophthalmologica Scandinavica 2002
`
`more advantageous to use corticosteroid
`containing eye drops of greater bioavail-
`ability. Furthermore,
`topically applied
`corticosteroids are generally not effective
`in the posterior segment of the eye and,
`therefore,
`systemic corticosteroids are
`needed to fight inflammatory disease in
`this area.
`Corticosteroids are generally lipophilic
`and dissolve very poorly in water. The
`commercially available eye drop formu-
`lations solve this dilemma by forming
`prodrugs, usually acetate or phosphate
`esters such as prednisolone acetate (Pred
`forte A, Pred mild A) and dexame-
`thazone phosphate or suspensions, such
`as dexamethazone alcohol
`suspension
`(MaxidexA).
`Various researchers have studied the
`penetration of topically applied ocular
`steroids into the anterior chamber of the
`human eye (Watson et al. 1988; McGhee
`et al. 1990). They found that of the com-
`mercially available formulations, those
`
`containing 1% prednisolone acetate (Pred
`forteA) gave the highest concentration in
`the aqueous humour per average 96 ng/
`mL. Eye drops containing 0.1% dexa-
`methasone alcohol suspension (Maxid-
`exA) gave a considerably lower concen-
`tration. However, if we take into account
`the fact that dexamethasone is seven times
`more potent than prednisolone, then the
`dexamethasone concentration obtained in
`the aqueous humour corresponded to
`about 60 ng/mL of prednisolone. The most
`effective corticosteroid eye drops available
`today give aqueous humour concentration
`of
`less
`than 100 ng/mL (prednisolone
`equivalents). This bioavailability can be
`improved through the use of cyclodextrin
`formulation, where a single drop topical
`application gives aqueous humour con-
`centration of about 140 ng/mL (pred-
`nisolone equivalents) and also extends its
`duration in the eye, as will be discussed
`later.
`The
`
`concentrations
`
`corticosteroid
`
`Table 1. Cyclodextrins in topical formulations for ocular drug delivery.
`
`Cyclodextrin
`
`References
`
`achieved in the aqueous humour from ap-
`plication of Maxidex A or Pred Forte A
`is usually sufficient for mild to moderate
`ocular inflammation. More potent for-
`mulations may allow topical treatment of
`more severe intraocular
`inflammation
`and also less frequent applications for
`mild to moderate inflammation.
`
`Physiological considerations
`In ophthalmology, local drug administra-
`tion in the form of topically applied low
`viscosity aqueous eye drop solutions is
`generally preferred. Topically applied
`drugs must be, at least to some degree,
`soluble in the aqueous tear fluid. How-
`ever, they must also be somewhat lipid-
`soluble in order to penetrate the lipophil-
`ic corneal epithelium, through the cor-
`neal stroma and the lipophilic endo-
`thelium into the aqueous humour (Ahm-
`ed et al. 1987; Wang et al. 1991). In other
`words, for successful formulation in an
`aqueous eye drop solution. a drug must
`be both water-soluble (i.e. hydrophilic)
`and
`lipid-soluble
`(i.e.
`hydrophobic)
`(Loftsson & Stefa´nsson 1997). The con-
`tinuous secretion of tear fluid adds to this
`difficulty by limiting the contact time of
`topically applied drugs with the eye sur-
`face, which again reduces their ocular
`bioavailability,
`especially after appli-
`cation in low viscosity aqueous eye drop
`solutions
`(Chrai et al. 1973). Conse-
`quently, less than 5% of a topically ap-
`plied drug is absorbed through the cor-
`nea into the eye (Gangrade et al. 1996;
`Loftsson & Järvinen 1999; Washington
`et al. 2001). Steroids used to treat ocular
`inflammation are lipophilic water-insol-
`uble compounds that have to be intro-
`duced into aqueous eye drop formu-
`lations as suspensions or as water-soluble
`prodrugs. In both cases, ocular bioavail-
`ability is seriously hampered by the low
`aqueous
`solubility or
`the hydrophilic
`properties of the penetrating molecules,
`respectively.
`In addition,
`insufficient
`chemical stability of the steroid prodrugs
`in aqueous solution, as well as poor in
`vivo conversion to parent steroid, has
`limited their use in ophthalmology (Tam-
`mara & Crider 1996).
`Common adjuvants to aqueous eye
`drop formulations can enhance ocular
`bioavailability of steroids by reducing the
`barrier function of, for example, the cor-
`nea (e.g. benzalkonium chloride and
`other surfactants (Lang & Stiemke 1996)
`or by increasing the contact time of the
`drug with the eye surface (e.g. viscosity
`enhancers such as water-soluble poly-
`
`145
`
`Drug
`
`Acetazolamide
`
`Anandamides
`Cannabinoids (various)
`Cyclosporin
`
`Dehydroepiandrosterone
`Dexamethasone
`
`Diclofenac
`Dipivefrine
`Fluorometholone
`Hydrocortisone
`
`Loteprednol etabonate
`Pilocarpine
`
`Prostaglandins
`Talidomide
`Tropicamide
`D9-Tetrahydrocannobinol
`
`HPbCD
`
`HPbCD
`HPbCD
`aCD
`
`HPbCD
`HPbCD
`
`(Loftsson et al. 1994;
`Loftsson et al. 1996)
`(Jarho et al. 1996;Pate et al. 1996)
`(Pate et al. 1998)
`(Kanai et al. 1989;
`Sasamoto et al. 1991;
`Cheeks et al. 1992
`(Kearse et al. 2001)
`(Usayapant et al. 1991;
`Loftsson et al. 1994;
`Kristinsson et al. 1996;
`Gavrilin et al. 1999)
`(Reer et al. 1994)
`(Jarho et al. 1997)
`(Morita et al. 1996)
`(Davies et al. 1997;
`Bary et al. 2000
`(Reddy et al. 1996)
`HPbCD, DMbCD
`aCD, bCD, HEbCD, HPbCD (Freedman et al. 1993;
`Järvinen et al. 1994;
`Keipert et al. 1996;
`Siefert & Keipert 1997)
`(Wheeler 1991)
`(Siefert et al. 1999)
`(Cappello et al. 2001)
`(Green & Kearse 2000;
`Kearse & Green 2000)
`
`HPbCD, RMbCD
`SBEbCD
`HPgCD
`HPbCD
`
`SBEbCD
`
`HPbCD
`HPbCD
`HPbCD
`aCD, bCD, HPbCD, gCD
`
`HPbCD 2-hydroxypropyl-b-cyclodextrin
`aCD a-cyclodextrin
`RMbCD randomly methylated b-cyclodextrin
`SBEbCD sulfobutylether b-cyclodextrin
`HPgCD 2-hydroxypropyl-g-cyclodextrin
`DMbCD heptakis (2,6-di-O-methyl)-b-cyclodextrin
`HEbCD hydroxyethyl-b-cyclodextrin
`bCD b-cyclodextrin
`gCD g-cyclodextrin
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1041, Page 2
`
`

`

`Acta Ophthalmologica Scandinavica 2002
`
`water-insoluble steroids as aqueous eye
`drop solutions (Usayapant et al. 1991;
`Loftsson et al. 1994; Kristinsson et al.
`1996; Morita et al. 1996; Reddy et al.
`1996; Davies et al. 1997; Gavrilin et al.
`1999; Bary et al. 2000; Kearse et al.
`2001). Furthermore, the chemical sta-
`bility of the drug molecule is enhanced by
`the inclusion complexation (Loftsson &
`Brewster 1996). This increases the shelf-
`life of the aqueous eye drop formulation.
`Once included in the cyclodextrin cav-
`ity,
`the drug molecules may be dis-
`sociated from the cyclodextrin molecules
`through complex dilution in the aqueous
`tear fluid. The included drug may also be
`replaced by some other suitable molecule
`(such as lipids), or,
`if the complex is
`located in close approximation to a lipo-
`philic biological membrane (such as the
`eye cornea), the guest may be transferred
`to the matrix for which it has the highest
`affinity. Importantly, since no covalent
`bonds are formed or broken during the
`guest-host complex formation, the com-
`plexes are in dynamic equilibrium with
`free drug and cyclodextrin molecules.
`The effects of cyclodextrins on drug
`solubility, permeability, chemical stability
`and delivery through biological mem-
`branes have been investigated by a number
`of research groups (Rajewski & Stella
`1996; Uekama et al. 1998; Loftsson &
`Järvinen 1999; Masson et al. 1999; Stella
`et al. 1999; Uekama 1999; Loftsson &
`Masson 2001). Their studies show that hy-
`drophilic cyclodextrins act as true carriers
`by keeping the lipophilic water-insoluble
`drug molecules in solution and delivering
`them to the membrane surface where they
`
`form inclusion complexes with
`trins
`many lipophilic molecules through a pro-
`cess in which water molecules located in-
`side the central cavity are replaced by
`either a whole molecule, or, more fre-
`quently, by some lipophilic structure of
`the molecule. Cyclodextrin complexation
`of a drug molecule changes the physico-
`chemical properties of the drug, such as
`its aqueous solubility and chemical sta-
`bility (Loftsson & Brewster 1996). Since
`the cyclodextrin molecule is hydrophilic
`on the outside, the complex formation
`usually increases the water-solubility of
`lipophilic water-insoluble drugs. Thus, it
`has been possible through cyclodextrin
`complexation to formulate
`lipophilic
`
`Fig. 2. The mechanism of drug (D) penetration into the eye from an aqueous cyclodextrin (CD)
`containing eye drop solution in the tear film. Modified from Loftsson & Järvinen (1999) with
`permission from Advanced Drug Delivery Reviews.
`
`Fig. 1. b-Cyclodextrin.
`
`mers). Specialized ocular delivery systems
`such as hydrogels, microemulsions, solid
`inserts and liposomes have also been de-
`signed in order to enhance bioavailability
`of
`topically applied ophthalmic drugs
`(Reddy 1996). However, these have never
`gained much popularity, due to both their
`side-effects (such as blurred vision and
`local irritation) and their instability (i.e.
`limited shelf-life).
`Cyclodextrins are novel, chemically
`stable adjuvants that enhance ocular bio-
`availability of ophthalmic drugs without
`affecting the barrier function of the eye
`or increasing the viscosity of the aqueous
`eye drop formulation (Loftsson & Mas-
`son 2001).
`
`Cyclodextrins
`Cyclodextrins are a group of structurally
`related natural products formed during
`bacterial digestion of cellulose. These cyc-
`lic oligosaccharides consist of
`(a-1,4)-
`linked a-D-glucopyranose units with a hy-
`drophilic outer surface and a lipophilic
`central cavity. The natural a-, b- and g-
`cyclodextrins consist of six, seven and
`eight glucopyranose units (Fig. 1), respec-
`tively. The aqueous solubility of these
`natural cyclodextrins is somewhat limited
`and thus several different water-soluble
`derivatives have been synthesized. Cyclo-
`dextrin derivatives which have been ap-
`plied in ophthalmology include the hydro-
`xypropyl derivatives of b- and g-cyclodex-
`trin,
`the
`randomly methylated
`b-
`cyclodextrin and sulfobutylether b-cyclo-
`dextrin (Table 1).
`In an aqueous environment, cyclodex-
`
`146
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1041, Page 3
`
`

`

`Acta Ophthalmologica Scandinavica 2002
`
`methasone for a space in the cyclodextrin
`cavity, thereby reducing the solubilizing
`effect of the cyclodextrin. At the same
`time, some other ingredients may have a
`solubilizing effect on the drug, thereby re-
`ducing
`the
`amount of
`cyclodextrin
`needed to solubilize the drug. Conse-
`quently, the amount of cyclodextrin in-
`cluded in the aqueous eye drop formu-
`lation has to be based on availability
`studies performed on the actual eye drop
`formulation which must
`contain all
`necessary excipients (e.g. preservatives,
`polymers and buffer salts).
`It is possible to increase drug availabil-
`ity in aqueous cyclodextrin formulations
`by including small amounts of water-sol-
`uble polymer. Polymers enhance the
`cyclodextrin complexation of the drug,
`thereby reducing the amount of cyclodex-
`trin needed in the formulation, while sim-
`ultaneously enhancing the absorption of
`the drug/cyclodextrin complex to the eye
`surface through the formation of ternary
`complexes or co-complexes (Kristinsson
`et al. 1996). This increases the drug avail-
`ability at the eye surface (Loftsson 1998;
`Loftsson & Järvinen 1999). The addition
`of 0.10% hydroxypropyl methylcellulose
`increases the apparent stability constant
`of
`dexamethasone/2-hydroxypropyl-b-
`cyclodextrin complex from 1200 m»1 to
`1600 m»1 (Loftsson & Stefa´nsson 1997).
`At the same time, the polymer increases
`the availability of dexamethasone in the
`aqueous eye drop formulation (Kristins-
`son et al. 1996). Using the described op-
`
`Fig. 3. The effect of 2-hydroxypropyl-b-cyclodextrin (HPbCD) concentration on the flux of dexa-
`methasone from an aqueous HPbCD solution containing 0.5% (w/v) dexamethasone through a
`4). The dexamethasone was in suspen-
`semipermeable cellophane membrane (mean ” SEM, n
`sion at HPbCD concentration below 5% but in solution at higher HPbCD concentrations. Modi-
`fied from Loftsson et al. (1994) with permission from the International Journal of Pharmaceutics.
`
`enough cyclodextrin is added to the ve-
`hicle to solubilize the entire drug. Figure
`3 shows that it is very important to
`optimize the dexamethasone release from
`an aqueous eye drop formulation by ad-
`justing the cyclodextrin concentration in
`the aqueous eye drop formulation. Too
`much or too little cyclodextrin will result
`in less than optimum drug availability.
`Some of the ingredients of the eye drop
`formulation will compete with dexa-
`
`partition from the cyclodextrin cavity into
`the lipophilic membrane. The relatively
`lipophilic membrane has low affinity for
`the large hydrophilic cyclodextrin mol-
`ecules or the hydrophilic drug/cyclodex-
`trin complexes, which thus remain in the
`aqueous skin exterior, e.g. the aqueous
`tear fluid. Conventional penetration en-
`hancers, such as benzalkonium chloride,
`disrupt the ophthalmic barrier, whereas
`hydrophilic cyclodextrins enhance drug
`penetration into the eye by carrying the
`lipophilic water-insoluble drug molecules
`through the aqueous mucin layer and
`thereby increasing drug availability at the
`lipophilic eye surface (Fig. 2) (Loftsson &
`Masson 2001).
`
`Formulation with cyclodextrin
`their
`Since neither cyclodextrins nor
`complexes are absorbed into lipophilic
`barriers, cyclodextrins can both increase
`and decrease drug availability at the eye
`surface. For example, the effect of cyclo-
`dextrin
`concentration
`on
`the
`per-
`meability of the lipophilic water-insoluble
`drug dexamethasone through semiperme-
`able membrane is shown in Fig. 3. At low
`cyclodextrin concentrations, when the
`drug is in suspension, the flux of the drug
`increases with increasing cyclodextrin
`concentration. At higher cyclodextrin
`concentrations, when the entire drug is in
`solution, the flux decreases with increas-
`ing cyclodextrin concentration. Maxi-
`mum permeability is observed when just
`
`Fig. 4. Dexamethasone concentration in aqueous humour of rabbits after administration of 50 mL
`of 1.3% dexamethasone in an aqueous cyclodextrin solution or a 0.1% dexamethasone alcoholic
`suspension (MaxidexA) (O) (mean ” SEM, n
`3). Modified from Loftsson et al. (1994) with per-
`mission from the International Journal of Pharmaceutics.
`
`147
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1041, Page 4
`
`

`

`Acta Ophthalmologica Scandinavica 2002
`
`eye
`timization technologies, aqueous
`drops containing 0.32, 0.67 and 1.3% (w/
`v) dexamethasone were prepared and
`tested both in animals and humans.
`
`In vivo observations
`Dexamethasone (1.3% w/v) was tested in
`English brown rabbits in an aqueous eye
`drop solution containing 2-hydroxyprop-
`yl-b-cyclodextrin and MaxidexA (Lofts-
`son et al. 1994). A single drop of the
`solution was applied in the rabbit’s eye
`and aqueous humour
`samples with-
`drawn at specified times following the
`administration. Dexamethasone
`(0.1%
`w/v) alcohol suspension (MaxidexA, Al-
`con Inc, Texas, USA) was used for con-
`trol. The 1.3% dexamethasone/2-hydro-
`xypropyl-b-cyclodextrin eye drops gave a
`significantly higher
`concentration of
`dexamethasone in the aqueous humour
`than did Maxidex, even though the dif-
`ference in concentration in the aqueous
`humour was less than the 13-fold differ-
`ence in the concentration of dexametha-
`sone in the eye drop. Four hours after
`the application of MaxidexA, the con-
`centration of dexamethasone
`in the
`aqueous humour was essentially zero,
`whereas the cyclodextrin-dexamethasone
`solution gave about 100 ng/mL (Fig. 4).
`The
`cyclodextrin-dexamethasone
`eye
`drop solution was well tolerated and no
`irritation was seen on clinical examina-
`tion of the rabbits.
`The ocular absorption of dexametha-
`sone eye drops containing 2-hydroxypro-
`pyl-b-cyclodextrin was also tested in hu-
`man patients and compared with Maxi-
`dexA (0.1% dexamethasone
`alcohol
`suspension). The patients received the
`eye drops at a certain time prior to cat-
`aract surgery and, at the time of catar-
`act surgery, an aqueous humour sample
`was withdrawn
`and
`dexamethasone
`levels determined. Figure 5 shows the
`dexamethasone
`concentration in the
`aqueous humour after administration of
`0.32% dexamethasone/2-hydroxypropyl-
`b-cyclodextrin and MaxidexA (Kristins-
`son et al. 1996). The concentration of
`dexamethasone in the aqueous humour
`was significantly higher (P , 0.001) and
`the area under the curve was 2.6 times
`higher with the 0.32% cyclodextrin-
`dexamethasone eye drop solution than
`with MaxidexA. The peak concentration
`of dexamethasone did not increase when
`the dexamethasone concentration in the
`aqueous
`cyclodextrin containing
`eye
`drops was increased from 0.32 to 0.67%
`(w/v) (Fig. 6). However, as can be seen
`
`148
`
`by concentration values obtained 9 hr
`after administration, the duration of ac-
`tivity was increased (Table 2). It is inter-
`esting to compare these results with the
`measurements of Watson and associates
`and McGhee and associates (see Table 2)
`(Watson et al. 1988; McGhee
`et al.
`1990). The 0.32% (w/v) dexamethasone
`solution gives a considerably higher ef-
`
`fective concentration in the aqueous hu-
`mour than does prednisolone acetate,
`which is the most potent corticosteroid
`eye drop on the market.
`Figure 6 shows the effect of the co-
`complexation involving the water-soluble
`polymer, hydroxypropyl methylcellulose,
`on the dexamethasone bioavailability in
`vivo. The two eye drop solutions were
`
`Fig. 5. Dexamethasone concentration in aqueous humour after administration of 1 drop (50 mL) of
`0.32% dexamethasone in an aqueous cyclodextrin solution (?)or a 0.1% dexamethasone alcoholic
`suspension (MaxidexA) (O). The concentration (mean ” SEM, n
`3) is shown at appropriate time
`points after administration of the eye drops to human volunteers. Reprinted from Kristinsson
`et al. (1996) with permission from Investigative Ophthalmology and Visual Science.
`
`Fig. 6. Dexamethasone concentration in aqueous humour after administration of 1 drop (50 mL)
`of 0.67% dexamethasone in an aqueous cyclodextrin solution; the dexamethasone/cyclodextrin/
`polymer co-complex (?), the simple dexamethasone/cyclodextrin complex (O). The concentration
`3) is shown at appropriate time points after administration of the eye drops to
`(mean ” SEM, n
`human volunteers. Reprinted from Kristinsson et al. (1996) with permission from Investigative
`Ophthalmology and Visual Science.
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1041, Page 5
`
`

`

`Acta Ophthalmologica Scandinavica 2002
`
`Table 2. Adjusted mean peak concentration (” SEM) of dexamethasone and prednisolone acetate,
`and the concentration at „9 hrs, in aqueous humour of human volunteers after topical adminis-
`tration. Concentrations are adjusted for potency of prednisolone, which is a seven-fold weaker
`steroid than dexamethasone.
`
`Eye drop solution
`
`Mean peak
`concentration
`(ng/ml)
`
`Concentration
`at „9 hrs
`(ng/mL
`
`141 ” 36
`Dexamethasone 0.32%
`130 ” 50
`Dexamethasone 0.67%
`60 ” 21
`Maxidex*
`96 ” 19
`Prednisolone acetate 1%
`*MaxidexA contains 0.1% dexamethasone alcoholic suspension
`Modified from Kristinsson et al. 1996; McGhee et al. 1990; Schoenwald et al. 1987).
`
`0
`18 ” 5
`0
`–
`
`for the study formu-
`identical except
`lation’s co-complex formation (induced
`through heating) between the drug/cyclo-
`dextrin complex
`and hydroxypropyl
`methylcellulose. The control formulation
`contained a simple drug/cyclodextrin
`complex. Formation of the co-complex
`resulted in significant enhancement of the
`bioavailability of the drug (Kristinsson et
`al. 1996).
`
`Clinical studies
`Saari et al. (1998) studied the use of de-
`xamethazone-cyclodextrin eye drops fol-
`lowing cataract surgery. Eye drops con-
`taining 0.67% dexamethazone-cyclodex-
`trin and used once per day were compared
`with a 0.1% dexamethazone used three
`times per day. Cell flare measurements of
`the aqueous humour and clinical evalu-
`ation indicated that the two treatment
`regimens were equally clinically efficient.
`Once per day application of the cyclodex-
`trin dexamethazone
`formulation was
`quite effective in controlling postoperative
`inflammation following cataract surgery.
`
`Conclusions
`Cyclodextrins make it possible to formu-
`late lipophilic drugs in aqueous eye drop
`solutions. This may be useful for the for-
`mulation of a variety of lipophilic drugs
`that hitherto have not been available as
`eye drops or in suboptimal formulations.
`Steroid drugs, including corticosteroids,
`are a good example of such drugs. They
`are lipophilic and have only been avail-
`able in eye drops as prodrugs or suspen-
`sions with limited concentration and bio-
`availability. With cyclodextrins, it is poss-
`ible to increase the drug concentration
`and bioavailability and create formu-
`lations that offer more effective and less
`
`frequent treatment schedules for patients
`with ocular inflammation.
`
`References
`Ahmed I, Gokhale RD, Shah MV & Patton
`TF (1987): Physicochemical determinants of
`drug diffusion across the conjunctiva, sclera,
`and cornea. J Pharm Sci 76: 583–586.
`
`Bary AR, Tucker IG & Davies NM (2000):
`Considerations in the use of hydroxypropyl-
`b-cyclodextrin in the formulation of aque-
`ous ophthalmic solutions of hydrocortisone.
`Eur J Pharm Biopharm 50: 237–244.
`Cappello B, Carmignani C, Iervolino M, Ro-
`tonda MIL & Saettone MF (2001): Solubil-
`ization of tropicamide by hydroxypropyl-b-
`cyclodextrin and water-soluble polymers: in
`vitro/in vivo studies. International J Pharm
`213: 75–81.
`Cheeks L, Kaswan RL & Green K (1992): In-
`fluence of vehicle and anterior chamber pro-
`tein concentration on cyclosporin penetra-
`tion through the isolated rabbit cornea.
`Curr Eye Res 11: 641–649.
`Chrai SS, Patton TF, Mehta A & Robinson JR
`(1973): Lacrimal and instilled fluid dynamics
`in the rabbit eye. J Pharm Sci 62: 1112–1121.
`Davies NM, Wang G & Tucker IG (1997):
`Evaluation of a hydrocortisone/hydroxypro-
`pyl-b-cyclodextrin solution for ocular drug
`delivery. Int J Pharm 156: 201–209.
`van Dorne H (1993): Interaction between
`cyclodextrins and ophthalmic drugs. Eur J
`Pharm Biopharm 39: 133–139.
`Freedman KA, Klein JW & Crosson CE
`(1993): Beta-cyclodextrins enhance biovail-
`ability of pilocarpine. Curr Eye Res 12: 641.
`Gangrade NK, Gaddipati NB, Ganesan
`MG & Reddy IK (1996): Topical ophthalmic
`formulations: basic considerations. In: Ocu-
`lar Therapeutics and Drug Delivery. Reddy
`IK (ed.). Technomic Publishers. Lancaster,
`UK. 377–403.
`Gavrilin MV, Kompantseva EV, Gusova BA,
`Ushakova LS, Makarova VA & Karpenya
`
`LI (1999): Dexamethasone eye drops based
`on the products of its interaction with 2-hy-
`synthesis and
`droxypropyl-b-cyclodextrin:
`study. Pharm Chem J 33: 160–163.
`Green K & Kearse EC(2000): Ocular penetra-
`tion of
`topical D9-tetrahydrocannabinol
`from rabbit corneal or cul-de-sac appli-
`cation site. Curr Eye Res 21: 566–570.
`Jarho P, Järvinen K, Urtti A, Stella VJ &
`Järvinen T (1997): The use of cyclodextrins
`in ophthalmic formulations of dipivefrine.
`Int J Pharm 153: 225–233.
`Jarho P, Urtti A, Pate DW, Suhonen P &
`Järvinen T (1996): Increase in aqueous solu-
`bility, stability and in vitro corneal per-
`meability of anandamide by hydroxypropyl-
`b-cyclodextrin. Int J Pharm 137: 209–217.
`Järvinen K, Järvinen T, Thompson DO & Stel-
`la V (1994): The effect of modified b-cyclo-
`dextrin, SBE4-b-CD, on the aqueous solu-
`bility and ocular absorption of pilocarpine.
`Curr Eye Res 13: 891–905.
`Kanai A, Alba RM, Takano T, Kobayashi C,
`Nakajima A, Kurihara K, Yokoyama T &
`Fukami M (1989): The effect on the cornea
`of alpha cyclodextrin vehicle for cyclosporin
`eye drops. Transplant Proc, Book 1 21:
`3150–3152.
`Kearse EC & Green K (2000): Effect of vehicle
`upon in vitro transcorneal permeability and
`intracorneal content of D9-tetrahydrocanna-
`binol. Curr Eye Res 20: 496–501.
`Kearse EC, McIntyre OL, Johnson MH, Phil-
`lips CI, Lathe R, Adams W & Green K
`(2001): Influence of dehydroepiandrosterone
`on rabbit intraocular pressure. Ophthalmic
`Res 33: 42–47.
`Keipert S, Fedder J, Böhm A & Hanke B
`(1996): Interactions between cyclodextrins
`and pilocarpine – as an example of a hydro-
`philic drug. Int J Pharm 142: 153–162.
`Kristinsson JK, Fridriksdo´ttir H, Tho´risdo´ttir
`S, Sigurdardo´ttir AM, Stefa´nsson E & Lofts-
`son T (1996): Dexamethasone-cyclodextrin-
`polymer co-complexes in aqueous eye drops.
`Invest Ophthalmol Vis Sci 37: 1199–1203.
`Lang JC & Stiemke MM (1996): Biological
`barriers to ocular delivery. In: Ocular Thera-
`peutics and Drug Delivery, a Multi-Disci-
`plinary Approach. Reddy IW (ed.). Techn-
`omic Publications. Lancaster, UK. 51–132.
`Loftsson T (1998): Increasing the cyclodextrin
`complexation of drugs and drug biovail-
`ability through addition of water-soluble
`polymers. Pharmazie 53: 733–740.
`Loftsson T & Brewster ME (1996): Pharma-
`ceutical applications of cyclodextrins. 1.
`Drug solubilization and stabilization. J
`Pharm Sci 85: 1017–1025.
`Loftsson T, Fridriksdo´ttir H, Stefa´nsson E,
`Tho´risdo´ttir S, Gudmundsson Ö & Sigtho´rs-
`son T (1994): Topically effective ocular hy-
`pertensive acetazolamide and ethoxyzolami-
`de formulations in rabbits. J Pharm Pharm-
`acol 46: 503–504.
`Loftsson T, Fridriksdottir H, Thorisdottir S &
`Stefa´nsson E (1994): The effect of hydroxyp-
`ropyl methylcellulose on release of dexame-
`
`149
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1041, Page 6
`
`

`

`Acta Ophthalmologica Scandinavica 2002
`
`thazone from aqueous 2-hydroxypropyl-b-
`cyclodextrin formulations. Int J Pharm 104:
`181–184.
`Loftsson T & Järvinen T (1999): Cyclodextrins
`in ophthalmic drug delivery. Adv Drug De-
`liv Rev 36: 59–79.
`Loftsson T & Masson M (2001): Cyclodextrins
`in topical drug formulations: theory and
`practice. Int J Pharm 212: 29–40.
`Loftsson T & Stefa´nsson E (1997): Effect of
`cyclodextrins on topical drug delivery to the
`eye. Drug Devel Ind Pharm 23: 473–481.
`Loftsson T, Stefa´nsson E, Kristinsson JK, Fri-
`driksdo´ttir H, Sverrisson T, Gudmundsdo´t-
`tir G & Tho´risdo´ttir S (1996): Topically ef-
`fective acetazolamide eye-drop solution in
`man. Pharm Sci 6: 277–279.
`Masson M, Loftsson T, Masson G & Stefa´ns-
`son E (1999): Cyclodextrins as permeation
`enhancers: some theoretical evaluations and
`in vitro testing. J Contr Rel 59: 107–118.
`McGhee CNJ, Watson DC, Midgley JM,
`Noble MJ, Dutton GN & Fern AI (1990):
`Penetration of synthetic corticosteroids into
`human aqueous humour. Eye 4: 526–530.
`Morita Y, Isowaki A & Kimura M (1996): Ef-
`fect of hydroxypropyl-g-cyclodextrin on
`ocular penetration of fluorometholone in vi-
`tro. 23rd International Symposium Contro.
`Release Bioact. Mater. Controlled Release
`Society. Kyoto, Japan. 451–452.
`Pate DW, Järvinen K, Urtti A, Jarho P, Mette
`F, Mahadevan V & Järvinen T (1996): Ef-
`fects of topical anandamides on intraocular
`pressure in normotensive rabbits. Life Sci
`58: 1849–1860.
`Pate DW, Järvinen K, Urtti A, Mahadevan
`V & Järvinen T (1998): Effect of the CB 1
`receptor antagonist, SR 141716A, on canna-
`binoid-induced ocular hypertension in nor-
`motensive rabbits. Life Sci 63: 2181–2188.
`Rajewski RA & Stella VJ (1996): Pharmaceut-
`ical applications of cyclodextrins. 2. In vivo
`drug delivery. J Pharm Sci 85: 1142–1168.
`Reddy IW, ed. (1996): Ocular Therapeutics and
`Drug Delivery, a Multi-Disciplinary Ap-
`proach. Technomic Publications, Lancaster,
`UK.
`
`Reddy IK, Khan MA, Wu WM & Bodor NS
`(1996): Permeability of a soft steroid, lotep-
`rednol etabonate, through an excised rabbit
`cornea. J Ocul Pharmacol Ther 12: 159–167.
`Reer O, Bock TK & Müller BW (1994): In vitro
`corneal permeability of diclofenac sodium in
`formulations containing cyclodextrins com-
`pared to commercial product voltaren
`ophtha. J Pharm Sci 83: 1345–1349.
`Saari KM, Jyrkkiö H, Seppä H, Loftsson T &
`Stefa´nsson E (1998): Acute and chronic
`postoperative inflammatory reactions after
`cataract extraction and intraocular lens im-
`plantation. Uveitis Today 1158: 99–102.
`Sasamoto Y, Hirose S, Ohno S, Onee´ K &
`Matsuda H (1991): Topical application of
`ciclosporin ophthalmic solution containing
`alpha-cyclodextrin in experimental uveitis.
`Ophthalmologica 203: 118–125.
`Schoenwald RD, Harris RG, Turner D &
`Knowles W (1987): Ophthalmic bioequival-
`ence of steroid/antibiotic combination for-
`mulations. Biopharm Drug Dispos 8: 527–
`548.
`Siefert B & Keipert S (1997): Influence of a-
`cyclodextrin and hydroxyalkylated b-cyclo-
`dextrin derivatives on the in vitro corneal
`uptake and permeation of aqueous pilocar-
`pine-HCl solutions. J Pharm Sci 86: 716–
`720.
`Siefert B, Pleyer U, Müller M, Hartmann C &
`Keipert S (1999): Influence of cyclodextrins
`on the in vitro permeability and in vivo ocu-
`lar distribution of
`talidomide. J Ocular
`Pharmacol Therap 15: 429–438.
`Stella VJ, Rao VM, Zannou EA & Zia V
`(1999): Mechanism of drug release from
`cyclodextrin complexes. Adv Drug Deliv
`Rev 36: 3–16.
`Tammara VK & Crider MA (1996): Prodrugs:
`a chemical approach to ocula

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket